From Theory to Practice: Applying Curren
โ
Edward D. Gomperts; Jan Astermark; Alessandro Gringeri; Jerome Teitel
๐
Article
๐
2008
๐
Elsevier Science
๐
English
โ 666 KB
Two bypassing agents are currently available to circumvent the need for factor FVIII in hemophilia A patients with inhibitors: the activated prothrombin complex FEIBA VH and recombinant activated factor VII (NovoSeven ยฎ ). Both products are highly effective in controlling bleeding in the presence of